Diabetes Therapy

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE
Diabetes Therapy - - 2012
Andreas Liebl, Steven M. Jones, Alberto Goday, Marian Benroubi, Conxa Castell, Axel Haupt, Claudia Nicolay, Helen T Smith
Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Diabetes Therapy - Tập 10 - Trang 1623-1624 - 2019
Amar Ali, Steve Bain, Debbie Hicks, Phillip Newland Jones, Dipesh C. Patel, Marc Evans, Kevin Fernando, June James, Nicola Milne, Adie Viljoen, John Wilding
In the original publication, Table 2 note was incorrectly published as “SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m2. Individuals already treated with canagliflozin or empagliflozin who demonstrate renal decline may continue treatment until eGFR reaches < 45 mL/min/1.73 m2”.
The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study
Diabetes Therapy - Tập 8 - Trang 601-609 - 2017
So Ra Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Sodium glucose co-transporter 2 (SGLT2) inhibitors increase urinary glucose excretion (UGE) by reducing the renal threshold for glucose excretion, which results in decreased serum glucose concentrations in patients with type 2 diabetes mellitus (T2D). However, no study to date has determined whether larger increases in UGE after SGLT2 inhibitor treatment correspond to larger reductions in glycate...... hiện toàn bộ
Tác động sinh hóa não bộ của Pregabalin ở bệnh nhân mắc bệnh thần kinh đái tháo đường đau: Một thử nghiệm lâm sàng ngẫu nhiên có kiểm soát Dịch bởi AI
Diabetes Therapy - - 2018
Mats De Jaeger, Lisa Goudman, Peter Van Schuerbeek, Johan De Mey, Bart Keymeulen, Raf Brouns, Maarten Moens
Với sự phát triển của các công cụ hình ảnh thần kinh mới, việc đánh giá sự thay đổi về sinh hóa thần kinh ở những bệnh nhân gặp phải đau mãn tính và xác định cách mà các yếu tố này biến đổi trong quá trình điều trị bằng thuốc đã trở nên khả thi. Mục tiêu của nghiên cứu này là xem xét cơ chế sinh hóa thần kinh chính xác dưới tác động của liệu pháp pregabalin, sử dụng phổ cộng hưởng từ (1H-MRS), ở m...... hiện toàn bộ
#pregabalin #đau mãn tính #bệnh thần kinh đái tháo đường #nghiên cứu ngẫu nhiên #mù đôi #phổ cộng hưởng từ
Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
Diabetes Therapy - Tập 13 - Trang 1281-1298 - 2022
José M. González-Clemente, María García-Castillo, Juan J. Gorgojo-Martínez, Alberto Jiménez, Ignacio Llorente, Eduardo Matute, Cristina Tejera, Aitziber Izarra, Albert Lecube
Dapagliflozin is a selective sodium–glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction and chronic kidney disease. In all indications, treatment can be initiated in adults with estimated glomerular filtration rate of at least 25 mL/min/1.73 m2. As monotherapy or as an additive therapy, dapagliflozi...... hiện toàn bộ
Skin Deep: Enhanced Variable May Help Explain Racial Disparities in Type 2 Diabetes and Prediabetes
Diabetes Therapy - Tập 8 - Trang 837-850 - 2017
Celia C. Lo, Joanna Lara, Tyrone C. Cheng
The study refined definitions of type 2 diabetes and prediabetes (Pre-/T2D) via its four-category outcome variable. Respondents were identified as Pre-/T2D on the basis of (a) doctor’s diagnosis only (i.e., managed Pre-/T2D); (b) biomarker only (i.e., undiagnosed Pre-/T2D); or (c) both diagnosis and biomarker (i.e., unmanaged Pre-/T2D). The reference was Pre-/T2D not indicated. We linked the outco...... hiện toàn bộ
Number-Based Approach to Insulin Taxonomy
Diabetes Therapy - Tập 6 - Trang 469-479 - 2015
Sanjay Kalra, Yashdeep Gupta
This article describes a number-based system for the classification of insulin regimes. It utilizes a patient-centered variable (number of injections per day) and pharmacokinetic/dynamic characteristics to craft a taxonomic system that is able to incorporate all available insulin preparations and coformulations. This framework of systematics is robust enough to include various molecules that have ...... hiện toàn bộ
Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK
Diabetes Therapy - Tập 8 - Trang 1175-1185 - 2017
Marc Evans, Sayeed Achha, Cheryl Neslusan
Diabetes-related costs make up a large portion of healthcare expenditures in the UK. Many of these costs are related to treatment of diabetes-related complications. Reducing HbA1c to <7.0% (53 mmol/mol) reduces the incidence of complications and comorbidities. Metformin plus sulfonylurea is the most common dual oral combination therapy in the UK. The costs of achieving HbA1c <7.0% in patients inad...... hiện toàn bộ
Personality Traits, Metabolic Control and the Use of Insulin Pump Functions in Adults With Type 1 Diabetes: An Observational Single-Visit Study
Diabetes Therapy - - 2020
Agnieszka Niemiec, Agata Juruć, Piotr Molęda, Krzysztof Safranow, Lilianna Majkowska
While a few studies have assessed the association between personality and metabolic outcomes in children and adolescents with type 1 diabetes (T1DM), there have been none in adults or in subjects treated with insulin pumps, and hypoglycaemic episodes have not been considered in these studies. The aim of this observational single-visit study was to assess the association between personality traits ...... hiện toàn bộ
Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports
Diabetes Therapy - - 2019
Nandu Thalange, Torben Biester, Thomas Danne
Tổng số: 1,040   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10